|
|
 |
Hepatitis C is a global disease and it is estimated that over 3 million people in the US are infected with the virus, many of whom don’t know it yet. The disease is named for the target organ which the Hepatitis C virus attacks – hepatic (liver) cells. It is the major cause of cirrhosis of the liver, liver failure, and primary liver cancer (hepatocellular carcinoma). It is also responsible for the majority of liver transplants. The current treatment for Hepatitis C has severe side effects and the majority of symptomatic patients are not helped by the treatment. iTherX scientists are studying the molecular mechanisms involved in the first step in hepatitis C virus infection: entry into the liver cell. Our insights have enabled us to pioneer drugs which block viral entry: HCV Entry Inhibitors.
>>>read more |
|
|
 |
WHAT’S NEW?
March 15, 2011
ITHERX INITIATES PHASE 1B STUDY OF FIRST-IN-CLASS HEPATITIS C VIRUS ENTRY INHIBITOR ITX-5061
-- Preclinical Studies Show that ITX-5061 Prevents Hepatitis C from Invading Liver Cells...
ITHERX APPOINTS STEFAN ZEUZEM, M.D., AS CHAIR OF SCIENTIFIC AND CLINICAL ADVISORY BOARD
-- Distinguished International Hepatitis Expert to Head iTherX’s Elite Group of Advisors In Clinical Development of New Hepatitis C Therapeutic...
|
| |
|
 |
|
